Concepts (91)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Angiogenesis Inhibitors | 5 | 2023 | 311 | 1.110 |
Why?
|
| Macular Edema | 4 | 2023 | 50 | 0.940 |
Why?
|
| Macular Degeneration | 3 | 2022 | 59 | 0.930 |
Why?
|
| Ranibizumab | 2 | 2022 | 15 | 0.910 |
Why?
|
| Retinal Diseases | 2 | 2017 | 90 | 0.850 |
Why?
|
| Vascular Endothelial Growth Factor A | 3 | 2023 | 407 | 0.830 |
Why?
|
| Eye Diseases | 1 | 2020 | 53 | 0.740 |
Why?
|
| Ophthalmology | 1 | 2020 | 39 | 0.730 |
Why?
|
| Intravitreal Injections | 7 | 2023 | 67 | 0.660 |
Why?
|
| Visual Acuity | 5 | 2022 | 194 | 0.630 |
Why?
|
| Anemia, Aplastic | 1 | 2017 | 30 | 0.600 |
Why?
|
| Platelet-Derived Growth Factor | 1 | 2017 | 67 | 0.590 |
Why?
|
| Drugs, Investigational | 1 | 2017 | 37 | 0.580 |
Why?
|
| Delivery of Health Care | 1 | 2020 | 426 | 0.540 |
Why?
|
| Wet Macular Degeneration | 3 | 2022 | 25 | 0.430 |
Why?
|
| Chorioretinitis | 1 | 2012 | 10 | 0.430 |
Why?
|
| West Nile Fever | 1 | 2012 | 21 | 0.420 |
Why?
|
| Diabetic Retinopathy | 2 | 2023 | 87 | 0.410 |
Why?
|
| Clinical Trials as Topic | 1 | 2017 | 1169 | 0.400 |
Why?
|
| Muscular Dystrophy, Facioscapulohumeral | 1 | 2008 | 2 | 0.330 |
Why?
|
| Telangiectasis | 1 | 2008 | 6 | 0.330 |
Why?
|
| Glaucoma, Neovascular | 1 | 2008 | 5 | 0.330 |
Why?
|
| Facial Muscles | 1 | 2008 | 23 | 0.330 |
Why?
|
| Muscle Hypotonia | 1 | 2008 | 45 | 0.320 |
Why?
|
| Retinal Vessels | 1 | 2008 | 58 | 0.310 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2012 | 930 | 0.280 |
Why?
|
| Tomography, Optical Coherence | 3 | 2022 | 130 | 0.270 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 3 | 2023 | 70 | 0.260 |
Why?
|
| Diabetes Mellitus | 2 | 2023 | 806 | 0.260 |
Why?
|
| Vascular Endothelial Growth Factors | 1 | 2022 | 56 | 0.210 |
Why?
|
| Retinal Perforations | 1 | 2020 | 19 | 0.190 |
Why?
|
| Vitrectomy | 1 | 2020 | 52 | 0.190 |
Why?
|
| Choroidal Neovascularization | 1 | 2020 | 31 | 0.190 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2023 | 557 | 0.180 |
Why?
|
| Monitoring, Physiologic | 1 | 2020 | 268 | 0.170 |
Why?
|
| Humans | 14 | 2023 | 86601 | 0.170 |
Why?
|
| Disease Management | 1 | 2020 | 327 | 0.160 |
Why?
|
| Actinomyces | 1 | 2017 | 5 | 0.160 |
Why?
|
| Actinomycosis | 1 | 2017 | 12 | 0.150 |
Why?
|
| Eye Infections, Bacterial | 1 | 2017 | 14 | 0.150 |
Why?
|
| Endophthalmitis | 1 | 2017 | 21 | 0.150 |
Why?
|
| Treatment Outcome | 3 | 2023 | 7988 | 0.130 |
Why?
|
| Cell Adhesion Molecules | 2 | 2006 | 163 | 0.130 |
Why?
|
| Propylene Glycols | 1 | 2013 | 30 | 0.110 |
Why?
|
| Diagnosis, Differential | 1 | 2017 | 1565 | 0.110 |
Why?
|
| Sphingosine | 1 | 2013 | 71 | 0.110 |
Why?
|
| Fluorescein Angiography | 2 | 2013 | 96 | 0.100 |
Why?
|
| Bevacizumab | 1 | 2012 | 281 | 0.100 |
Why?
|
| Multiple Sclerosis | 1 | 2013 | 262 | 0.090 |
Why?
|
| Child, Preschool | 1 | 2017 | 3611 | 0.090 |
Why?
|
| Eye Enucleation | 1 | 2008 | 6 | 0.080 |
Why?
|
| Chromosomes, Human, Pair 4 | 1 | 2008 | 48 | 0.080 |
Why?
|
| Intraocular Pressure | 1 | 2008 | 54 | 0.080 |
Why?
|
| Laser Coagulation | 1 | 2008 | 54 | 0.080 |
Why?
|
| Immunosuppressive Agents | 1 | 2013 | 977 | 0.080 |
Why?
|
| Chromosome Deletion | 1 | 2008 | 229 | 0.080 |
Why?
|
| Trigeminal Ganglion | 1 | 2006 | 16 | 0.070 |
Why?
|
| Nervous System | 1 | 2006 | 86 | 0.070 |
Why?
|
| Herpes Simplex | 1 | 2006 | 202 | 0.060 |
Why?
|
| Keratitis, Herpetic | 1 | 2004 | 9 | 0.060 |
Why?
|
| Receptors, Virus | 1 | 2004 | 74 | 0.060 |
Why?
|
| Female | 6 | 2023 | 44507 | 0.060 |
Why?
|
| Eye | 1 | 2004 | 111 | 0.060 |
Why?
|
| Aged | 3 | 2020 | 18402 | 0.060 |
Why?
|
| Male | 5 | 2023 | 40956 | 0.060 |
Why?
|
| Fluocinolone Acetonide | 1 | 2022 | 8 | 0.050 |
Why?
|
| Drug Implants | 1 | 2022 | 34 | 0.050 |
Why?
|
| Herpesvirus 1, Human | 1 | 2004 | 244 | 0.050 |
Why?
|
| Pyrazoles | 1 | 2022 | 153 | 0.050 |
Why?
|
| Steroids | 1 | 2022 | 177 | 0.050 |
Why?
|
| Indoles | 1 | 2022 | 318 | 0.050 |
Why?
|
| Glucocorticoids | 1 | 2022 | 352 | 0.040 |
Why?
|
| Equipment Design | 1 | 2020 | 406 | 0.040 |
Why?
|
| Pyrimidines | 1 | 2022 | 370 | 0.040 |
Why?
|
| Middle Aged | 3 | 2023 | 25017 | 0.040 |
Why?
|
| Brain | 1 | 2006 | 2216 | 0.030 |
Why?
|
| Nectins | 2 | 2006 | 9 | 0.030 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2022 | 1313 | 0.030 |
Why?
|
| Retrospective Studies | 2 | 2020 | 8475 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2022 | 4210 | 0.030 |
Why?
|
| Mice, Inbred BALB C | 2 | 2006 | 1047 | 0.030 |
Why?
|
| Fingolimod Hydrochloride | 1 | 2013 | 29 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2013 | 684 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2020 | 6501 | 0.020 |
Why?
|
| United States | 1 | 2020 | 6665 | 0.020 |
Why?
|
| Viral Envelope Proteins | 1 | 2006 | 94 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 2004 | 303 | 0.020 |
Why?
|
| Viral Proteins | 1 | 2004 | 300 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2006 | 1753 | 0.010 |
Why?
|
| Mice | 2 | 2006 | 11352 | 0.010 |
Why?
|
| Animals | 2 | 2006 | 26581 | 0.010 |
Why?
|